In 2017, NIH awarded another $3 million grant to further develop the Hemanext ONE® RBC Processing and Storage System; the company also completed research that became the pivotal clinical study for obtaining CE Mark certification.
Recent Posts
- Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
- Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study
- AABB Science Innovation Forum Nov 2023
- Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®
- Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth